Page last updated: 2024-11-02

pamidronate and Hepatocellular Carcinoma

pamidronate has been researched along with Hepatocellular Carcinoma in 2 studies

Research Excerpts

ExcerptRelevanceReference
"This study presents 3 cases of refractory pain from bone metastases due to thyroid, colorectal and hepatocellular carcinoma."1.32[Bisphosphonate as an adjuvant therapy for the pain of bone metastases, 3 cases]. ( Hattori, S; Kudo, K; Miyakawa, H; Noguchi, T; Okuda, K, 2004)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hattori, S1
Miyakawa, H1
Okuda, K1
Kudo, K1
Noguchi, T1
Wada, A1
Fukui, K1
Sawai, Y1
Imanaka, K1
Kiso, S1
Tamura, S1
Shimomura, I1
Hayashi, N1

Other Studies

2 other studies available for pamidronate and Hepatocellular Carcinoma

ArticleYear
[Bisphosphonate as an adjuvant therapy for the pain of bone metastases, 3 cases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:2

    Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Diphosphonates; Female; Hum

2004
Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma.
    Journal of hepatology, 2006, Volume: 44, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movemen

2006